謝逸憲HSIEH, YI-HSIEN蘇建銘SU, JIAN-MINGJIAN-MINGSU醫學研究所碩士班2026-10-292025-07-1020252025-06-23https://handle.ncl.edu.tw/11296/7j8skkhttps://scholars.csmu.edu.tw/handle/123456789/36734腦部受到癌細胞侵襲其功能將可能出現不同程度的受損,且其治療難度普遍高於其他類型之癌症。腦瘤可依其起源區分為原發性與繼發性兩類。其中原發性腦瘤是指惡性腫瘤起始於腦部組織,通常依其來源細胞命名。臨床上最常見的原發性腦瘤的類型為膠質母細胞瘤。淋巴細胞胞質蛋白1(Lymphocyte cytosolic protein 1)是一種最初在造血細胞中發現的肌動蛋白結合蛋白在多種非造血部位的惡性腫瘤中發現。先前的研究發現LCP1過度表現有助於腫瘤進展,然而它在膠質母細胞瘤中的作用仍不清楚。本實驗的目的是研究 LCP1在膠質母細胞瘤中的潛在影響及其機制。我們首先分析TCGA及CGGA資料庫,發現LCP1在膠質母細胞瘤患者之腫瘤組織中的表達量顯著高於正常腦組織,並且會隨著腫瘤級別的升高而增加。膠質母細胞瘤患者的存活期也會隨著LCP1表達增加而減少。在細胞實驗中,使用GBM8401與M059K這兩株細胞來分析LCP1在膠質母細胞瘤細胞的表現。相較於正常的星狀細胞,膠質母細胞瘤細胞中的LCP1之表達量顯著升高。進一步以基因沉默方式抑制GBM8401與M059K 細胞株內生性的LCP1表達,分析抑制LCP1對於腦膠質細胞瘤中癌化和轉移的關係。發現抑制LCP1表達後會降低膠質母細胞瘤細胞的生長、遷移以及侵襲能力。接著搜尋TISIDB資料庫後發現在膠質母細胞瘤患者中LCP1的表達與趨化因子CXCL12及其受體CXCR4的表現呈高度正相關。我們將膠質母細胞瘤細胞的LCP1抑制後也觀察到CXCL12表達下降。同時我們也發現與上皮細胞表型相關之標記物E-cadherin表達上升;而與間質細胞表型相關之標記物,如Snail、Slug與N-cadherin表達下降。這說明LCP1與癌症轉移關鍵機制上皮間質轉化有關。綜合上述結果,我們證實抑制膠質母細胞瘤細胞LCP1表達後,可以抑制腫瘤細胞的生長及侵襲能力。LCP1也會藉由影響趨化因子CXCL12來減少癌症轉移的傾向。Once invaded by cancer cells, its functions may become impaired to varying degrees, and the treatment of brain malignancies is generally more challenging than that of other cancer types. Brain tumors can be classified into two categories based on their origin: primary and secondary. Primary brain tumors originate within the brain tissue itself and are typically named after the cell type from which they arise. Clinically, the most common type of primary brain tumor is glioblastoma. Lymphocyte cytosolic protein 1 (LCP1) is an actin-binding protein initially identified in hematopoietic cells, but has also been detected in various non-hematopoietic malignancies. Previous studies have indicated that overexpression of LCP1 contributes to tumor progression; however, its role in glioblastoma remains unclear. This study aims to investigate the potential function and underlying mechanisms of LCP1 in glioblastoma. By analyzing data from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA), we observed that LCP1 expression is significantly upregulated in glioblastoma tumor tissues compared to normal brain tissues, and its expression increases with tumor grade. Moreover, higher LCP1 expression is associated with reduced overall survival in glioblastoma patients. In cell-based experiments, we examined LCP1 expression in glioblastoma cell lines GBM8401 and M059K and found significantly elevated levels compared to normal astrocytes. Subsequently, we silenced endogenous LCP1 expression in both GBM8401 and M059K cells to assess its role in glioblastoma tumorigenesis and metastasis. LCP1 knockdown led to a marked reduction in cell proliferation, migration, and invasion. Further analysis using the TISIDB database revealed a strong positive correlation between LCP1 expression and the chemokine CXCL12 as well as its receptor CXCR4 in glioblastoma patients. In vitro, suppression of LCP1 also resulted in downregulation of CXCL12 expression. Additionally, we observed an upregulation of the epithelial marker E-cadherin and a downregulation of mesenchymal markers such as Snail, Slug, and N-cadherin, suggesting a role for LCP1 in epithelial-mesenchymal transition (EMT), a key mechanism in cancer metastasis. In conclusion, our findings demonstrate that inhibition of LCP1 expression in glioblastoma cells suppresses tumor growth and invasive capacity. LCP1 may also contribute to metastasis by modulating the expression of the chemokine CXCL12, highlighting its potential as a therapeutic target in glioblastoma.膠質母細胞瘤淋巴細胞胞質蛋白1上皮間質轉化GliomaLymphocyte cytosolic protein 1epithelial-mesenchymal transition探討淋巴細胞胞質蛋白1參與膠質母細胞瘤之癌化及轉移分子機制thesis